Abbott Laboratories: Beat — EPS $1.42, Revenue $13.01B
Earnings BeatQ3 2026 · Pre-market
@trystockwhiz
Did Abbott Laboratories (ABT) beat earnings today?
Yes, Abbott Laboratories (ABT) beat Wall Street analyst expectations for Q3 2026, reporting higher-than-expected EPS and higher-than-expected revenue.
Earnings Per Share+0.71% surprise
$1.42Actual
Expected: $1.41
vs. year ago +9.2%
Total Revenue+0.18% surprise
$13.01BActual
Expected: $12.99B
vs. year ago +14.5%
Released Oct 21 · 7:30 AM ET
Earning Report
| Metric | Q3 2026 | Q3 2025 | YoY Change % |
|---|---|---|---|
| Revenue | $13.01B | $11.37B | +14.5% |
| Revenue detail — reported lines | |||
| └─Nutrition | $2.26B | - | +5.1% |
| └─Pediatric | $1.06B | - | +8.8% |
| └─Adult | $1.20B | - | +2.0% |
| └─Diagnostics | $3.31B | $2.25B | +46.7% |
| └─Core Laboratory | $1.44B | - | +5.4% |
| └─Cancer Diagnostics | $968.00M | - | - |
| └─Rapid/Molecular Diagnostics | $899.00M | - | +1.1% |
| └─Established Pharmaceuticals | $1.61B | - | +6.8% |
| └─Key Emerging | $1.20B | - | +9.0% |
| └─Other Markets | $419.00M | - | +1.1% |
| └─Medical Devices | $5.83B | $5.45B | +6.9% |
| └─Rhythm Management | $752.00M | - | +9.7% |
| └─Electrophysiology | $873.00M | - | +15.0% |
| └─Heart Failure | $387.00M | - | +5.8% |
| └─Vascular | $786.00M | - | +5.4% |
| └─Structural Heart | $592.00M | $580.00M | +1.9% |
| └─Neuromodulation | $251.00M | - | -1.2% |
| └─Diabetes Care | $2.19B | - | +6.2% |
| Net Earnings | $920.00M | $1.64B | -44.1% |
| GAAP Diluted EPS | $0.53 | $0.94 | -43.6% |
| Adjusted Diluted EPS | $1.42 | $1.30 | +9.2% |
Financial Outlook / Guidance
| Metric | Q4 2026 Outlook | FY 2026 Outlook |
|---|---|---|
| Comparable Sales Growth | — | ~6.0% |
| Adjusted Diluted EPS | $1.62-$1.67 | $5.50-$5.55 |
Business Highlights
- ➤Received FDA approval for Libre Duo, the first dual glucose-ketone biowearable sensor.
- ➤Received CE Mark for Amulet 360 Left Atrial Appendage Occluder.
- ➤Launched Similac 360 Total Care Made With Whole Milk in the United States.
- ➤Received FDA approval for TactiFlex Duo Ablation Catheter, Sensor Enabled.
- ➤Launched SimpleScreen CRC, an FDA-approved blood-based colorectal cancer screening test.
- ➤Completed the acquisition of Exact Sciences on March 23, 2026.
- ➤Transferred Amplatzer Amulet device and accessories to Electrophysiology on January 1, 2026.
- ➤Declared a $0.63 per share quarterly dividend.
- ➤Increased dividend payout for 54 consecutive years.
- ➤Serves people in more than 160 countries through its global healthcare portfolio.
Management Commentary
Robert B. Ford, chairman and chief executive officer, Abbott
“Abbott delivered strong third-quarter results, reflecting balanced growth across our portfolio,”
Robert B. Ford, chairman and chief executive officer, Abbott
“With strong performance across multiple businesses and a robust pipeline of innovation, we are well-positioned to deliver sustainable growth in the years ahead.”